T4P, you are of course right, it is only a short matter of time now until the spring pops once more. The good thing about the value of where we sit now is the upside is substantial so probably good for us that the market is slow on the uptake.
Validation makes for a somewhat worry-free ride and hands ANP the power within negotiations… the ability to decline lowball offers with a degree of certainty and confidence behind them is a rear position for a bio spec and will only increase the likelihood of substantial value for shareholders.
Important to note that of the 28 drugs in the pipeline only 11 will carry the validation (being liver targeting Gen2), so ATL1103 is certainly turning out to be the goose to lay the golden egg for ANP. Actually, looking at all 11 in preclinical stages I’d say mipomersen and ATL1103 would be the pick of the bunch… ISIS have handed ATL1103 to ANP on a plate to help them grow imo
JMO, Good Luck!
ANP Price at posting:
25.0¢ Sentiment: LT Buy Disclosure: Held
